Explore 3 Stock Ideas & Industry Insights Download Free Report

800-234-336
Shopping Cart 0
countryflagNZ
Login

Scancell Holdings plc

Healthcare US SCNLF

0.3349USD
0.00(0%)

Last update at 2026-06-03T20:00:00Z

Day Range

0.310.31
LowHigh

52 Week Range

0.130.59
LowHigh

Fundamentals

  • Previous Close 0.33
  • Market Cap129.43M
  • Volume2500
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-11.38400M
  • Revenue TTM5.27M
  • Revenue Per Share TTM0.006
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-0.02

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-04-30 2022-04-30 2021-04-30 2020-04-30 2019-04-30
Type yearly yearly yearly yearly yearly
Date 2023-04-30 2022-04-30 2021-04-30 2020-04-30 2019-04-30
Income before tax -14.30400M -3.76800M -16.80500M -6.76800M -6.71401M
Minority interest - - - - -
Net income -11.93600M -2.06500M -15.47700M -5.50600M -5.62749M
Selling general administrative 5.02M 4.79M 3.35M 2.12M 2.58M
Selling and marketing expenses - - - - -
Gross profit 4.75M - - - -
Reconciled depreciation 0.90M 0.74M 0.25M 0.04M 0.02M
Ebit - -8.05200M -15.15400M -6.78200M -6.72901M
Ebitda - -7.31200M -14.90500M -6.73900M -6.70795M
Depreciation and amortization - 0.74M 0.25M 0.04M 0.02M
Non operating income net other - - - - -
Operating income -11.92000M -13.29900M -8.83400M -6.78200M -6.72901M
Other operating expenses - 13.30M 8.83M 6.78M 6.73M
Interest expense 1.22M 2.88M 1.65M 0.00000M 0.00000M
Tax provision -2.36800M -1.70300M -1.32800M -1.26200M -1.08652M
Interest income 0.28M 0.00400M 0.00300M 0.01M 0.02M
Net interest income -0.93100M 2.37M -7.97100M 0.01M 0.02M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - -1.70300M -1.32800M -1.26200M -1.08652M
Total revenue 5.27M 0.00000M 0.00000M 0.00000M -
Total operating expenses 17.19M 13.30M 8.83M 6.78M 6.73M
Cost of revenue 0.53M - - - -
Total other income expense net - 9.53M -7.97100M 0.01M 0.02M
Discontinued operations - - - - -
Net income from continuing ops -11.93600M -2.06500M -15.47700M -5.50600M -5.62749M
Net income applicable to common shares - -2.06500M -15.47700M -5.50600M -5.62800M
Preferred stock and other adjustments - - - - -
Breakdown 2023-04-30 2022-04-30 2021-04-30 2020-04-30 2019-04-30
Type yearly yearly yearly yearly yearly
Date 2023-04-30 2022-04-30 2021-04-30 2020-04-30 2019-04-30
Total assets 30.27M 38.52M 49.06M 8.82M 10.54M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets - - - - -
Total liab 36.50M 20.41M 29.57M 1.17M 1.21M
Total stockholder equity -6.23300M 18.11M 19.48M 7.65M 9.34M
Deferred long term liab - - - - -
Other current liab - 0.34M 0.06M 0.06M 0.06M
Common stock - 0.81M 0.81M 0.47M 0.39M
Capital stock 0.82M 0.81M 0.81M 0.47M 0.39M
Retained earnings -74.35600M -49.11900M -47.05400M -31.57700M -26.07120M
Other liab - 10.10M 12.03M - -
Good will 3.42M 3.42M 3.42M 3.42M 3.42M
Other assets - - - - -
Cash 19.92M 28.73M 41.11M 3.58M 4.56M
Cash and equivalents - - - - -
Total current liabilities 3.28M 2.45M 2.29M 1.17M 1.21M
Current deferred revenue - - - - -
Net debt - -20.54600M -25.65500M -3.44600M -4.55995M
Short term debt - 0.32M 0.21M 0.13M -
Short long term debt - - - - -
Short long term debt total - 8.18M 15.46M 0.13M -
Other stockholder equity - 66.41M 65.72M 38.76M 35.02M
Property plant equipment - 2.74M 0.97M 0.20M 0.06M
Total current assets 24.61M 32.36M 44.67M 5.21M 7.07M
Long term investments - - - - -
Net tangible assets - 14.70M 16.07M 4.23M 5.92M
Short term investments - - - - -
Net receivables 0.54M 3.19M 2.84M 1.33M 2.02M
Long term debt 18.48M 7.01M 15.18M - -
Inventory - - - - -
Accounts payable 2.97M 2.14M 2.09M 1.04M 1.21M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - - -
Deferred long term asset charges - - - - -
Non current assets total 5.66M 6.16M 4.39M 3.61M 3.47M
Capital lease obligations 1.05M 1.17M 0.27M 0.13M -
Long term debt total - - - - -
Breakdown 2023-04-30 2022-04-30 2021-04-30 2020-04-30 2019-04-30
Type yearly yearly yearly yearly yearly
Date 2023-04-30 2022-04-30 2021-04-30 2020-04-30 2019-04-30
Investments 0.08M -1.26400M -0.74100M -0.01300M 0.01M
Change to liabilities - 0.05M 1.05M -0.16400M 0.51M
Total cashflows from investing activities - -1.26400M -0.74100M -0.01300M 0.01M
Net borrowings - -0.39100M 23.35M -0.02700M -0.02700M
Total cash from financing activities - -0.92800M 46.08M 3.80M 1.28M
Change to operating activities - - - - -
Net income -11.93600M -3.76800M -16.80500M -6.76800M -6.71401M
Change in cash -8.80500M -12.38500M 37.53M -0.98500M -5.74322M
Begin period cash flow 28.73M 41.11M 3.58M 4.56M 10.30M
End period cash flow 19.92M 28.73M 41.11M 3.58M 4.56M
Total cash from operating activities -8.14000M -10.19300M -7.80300M -4.77200M -7.03295M
Issuance of capital stock 0.17M 0.00000M 24.14M 3.88M 1.36M
Depreciation 0.90M 0.74M 0.25M 0.04M 0.02M
Other cashflows from investing activities - 0.00400M 0.00300M 0.01M 0.01M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - 0.32M -0.59700M 0.31M -0.58000M
Sale purchase of stock - - - - -
Other cashflows from financing activities - -1.26400M 21.94M -0.07700M -0.08306M
Change to netincome - -9.24000M 6.98M 0.55M -1.35600M
Capital expenditures 0.20M 1.27M 0.74M 0.03M 0.00266M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.94M 0.37M 0.45M 0.14M -0.07099M
Stock based compensation 0.73M 0.69M 0.33M -0.01000M -0.25401M
Other non cash items 2.38M -8.22700M 7.97M 1.82M -0.01500M
Free cash flow -8.34300M -11.46100M -8.54700M -4.79900M -7.03561M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
SCNLF
Scancell Holdings plc		 - -% 0.33 - - 24.19 9.55 24.56 -10.6211
NVO
Novo Nordisk A/S		 2.31 5.51% 44.31 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.78 4.23% 44.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 14.76 3.44% 443.10 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.86 1.11% 625.81 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel immunotherapies and vaccines for the treatment of cancer and infectious disease. Its product candidates include SCIB1, an ImmunoBody cancer vaccine that is in Phase II for the treatment of metastatic melanoma; and SCIB2/iSCIB2 vaccine, which is under evaluation for the treatment of patients with solid tumors, including non-small cell lung cancer. It also develops Modi-1, a citrullinated peptides vaccine that is in phase I/II clinical trials for the treatment of solid tumors including triple negative breast, ovarian, renal, and head and neck cancers; and Modi-2, which targets homocitrullinated cancer antigens. In addition, the company focuses to develop SCOV1 and SCOV2 COVIDITY, a DNA vaccine against the SARS-CoV-2 virus. Scancell Holdings plc was founded in 1997 and is based in Oxford, the United Kingdom.

Scancell Holdings plc

Bellhouse Building, Oxford, United Kingdom, OX4 4GD

Key Executives

Name Title Year Born
Prof. Lindy Gillian Durrant Ph.D. Founder, CEO, Chief Scientific Officer & Director NA
Dr. Sally Elizabeth Adams Chief Devel. Officer & Director 1961
Mr. Keith Green Director of Fin. & Admin. and Company Sec. NA
Dr. Samantha Paston Ph.D. Head of Translational Research NA
Dr. Adrian Parry Ph.D. Head of Manufacturing NA
Ms. Akua Asare Head of Quality NA
Mr. Fayaz Master Head of Clinical Operations NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.